The genetic risk of schizophrenia: what we know in 2026

"Is schizophrenia genetic?" is one of the questions families ask most often after a diagnosis, and one of the most important to answer honestly. The short answer is yes — schizophrenia is among the most heritable conditions in psychiatry. The longer answer is more interesting and more nuanced: heritability is not destiny, no single gene "causes" the disorder, and family risk is real but lower than many people fear.

How we know it's heritable

Three main lines of evidence:

• Family studies — risk rises with closeness of biological relationship to an affected person. About 1% in the general population, ~9% with one affected sibling, ~10% with one affected parent, ~40% with both parents affected.
• Twin studies — concordance rates are roughly 40–50% in monozygotic (identical) twins versus 10–15% in dizygotic (fraternal) twins. The gap is the strongest evidence for genetic influence.
• Adoption studies — children of biological parents with schizophrenia raised by unaffected adoptive parents still have elevated risk, indicating the heritable component is biological rather than environmental.

Pooled estimates put heritability at roughly 60–80%. This is high — comparable to height, and higher than for many medical conditions traditionally considered "genetic."

What "polygenic" means

For decades researchers searched for "the schizophrenia gene." It does not exist. What does exist is a contribution from many — possibly hundreds or thousands — of common genetic variants, each with very small individual effects.

The Psychiatric Genomics Consortium (PGC) has run the largest genome-wide association studies (GWAS) in schizophrenia. By 2022 they had identified more than 280 distinct genomic regions associated with schizophrenia risk (Trubetskoy et al., Nature 2022; PubMed: 35396580). The implicated genes cluster in pathways relevant to brain development, synaptic function, and immune signalling — but no single variant comes anywhere close to "explaining" the disorder.

Polygenic risk scores

A polygenic risk score (PRS) sums up the effects of many small-effect variants into a single number. PRS for schizophrenia distinguishes affected from unaffected groups statistically — but at the individual level, a high PRS does not predict illness with anything like clinical certainty. People in the top decile of PRS have a few-fold elevated lifetime risk compared with the bottom decile, but the absolute risk remains modest. PRS is currently a research tool, not a diagnostic test.

Rare variants of large effect

Alongside the common-variant story, there is a smaller but important contribution from rare variants of larger effect:

• Copy number variations (CNVs) — chromosomal deletions or duplications. Several CNVs are well-established schizophrenia risk factors, including the 22q11.2 deletion (DiGeorge / velocardiofacial syndrome), 1q21.1 deletion, 15q13.3 deletion, and 16p11.2 duplication.
• 22q11.2 deletion syndrome deserves particular mention: roughly 1 in 4 individuals with this deletion develops schizophrenia or related psychotic illness. It is one of the strongest single genetic risk factors known.
• De novo mutations — newly arising mutations not inherited from either parent — also contribute, more so in cases without family history.

Rare variants account for a minority of cases but their large effect sizes have made them especially useful for biological research. Childhood-onset schizophrenia in particular shows enrichment for rare CNVs.

Gene-environment interaction

Genetic risk doesn't operate in isolation. Several environmental factors interact with genetic vulnerability:

• Heavy adolescent cannabis use — increases risk most in those with higher genetic loading
• Pregnancy and birth complications
• Severe childhood adversity
• Migration and chronic social stress
• Urban upbringing

The "stress-vulnerability" model that organises modern thinking holds that genetic loading sets a threshold; environmental factors push some individuals across it.

What family risk numbers actually mean

Risk numbers from family studies are sometimes presented in ways that frighten families more than they should. To put them in perspective:

• If you have a sibling with schizophrenia, your lifetime risk is roughly 9% — meaning a 91% chance you will not develop it
• If you have a parent with schizophrenia, your lifetime risk is roughly 10% — versus 1% baseline
• If you have a more distant affected relative (cousin, grandparent), the increase is small
• If both parents are affected, risk is roughly 40% — still less than half

Even with substantial genetic loading, most people do not develop schizophrenia.

What about genetic testing?

Routine genetic testing is not currently part of schizophrenia diagnosis or treatment for most patients. Specific testing for known CNVs is sometimes done in cases with childhood onset, intellectual disability, distinctive physical features, or strong family history — particularly to look for 22q11.2 deletion or other syndromes. Pharmacogenomic testing (looking at how individuals metabolise specific medications, e.g., CYP2D6 status) is increasingly available and can help guide medication choice in some cases.

The American College of Medical Genetics and several international bodies have published guidance on when genetic testing is appropriate in psychiatric assessment. This is best discussed with a psychiatrist or genetic counsellor.

What this means for family planning

People with schizophrenia, or with affected relatives, often ask whether to have children. There is no single right answer, but several points are useful:

• Even with a parent affected, the lifetime risk to a child is around 10% — meaning around 90% will not develop schizophrenia
• Genetic counselling can give individualised risk estimates
• Modifiable risk factors (avoiding heavy cannabis use in adolescence, supporting early intervention if symptoms emerge) can be planned for
• Many people with schizophrenia have raised healthy children

Why genetics research matters even now

Genetic findings are slowly but meaningfully shaping the field:

• Identification of biological pathways that may eventually become drug targets (immune, glutamate, synaptic-density pathways)
• Better understanding of overlap between schizophrenia and other psychiatric disorders
• Improved ability to study subgroups of patients with shared biology
• Movement toward more biologically informed classification of psychotic disorders

None of this has yet produced a "schizophrenia genetic test" or a targeted therapy. It is laying the groundwork for the next generation of treatments.

The bottom line

Schizophrenia is highly heritable, but heritability is not the same as inheritance of a specific gene. Risk is polygenic, modulated by environment, and never deterministic. Most people with affected relatives do not develop the disorder; most cases of schizophrenia occur in people without a striking family history. The science continues to advance — and so do the treatments that can change a person's trajectory regardless of genetic background.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.